China NT Pharma Group Co., Ltd. (HK:1011)
:1011
Top Page
China NT Pharma Group Co., Ltd.
(1011)
Select Model
Select Model
Rating:48Neutral
Price Target:
HK$0.75
▼(-10.48% Downside)
Action:ReiteratedDate:12/25/25
The score is primarily held down by very weak financial fundamentals (losses, negative equity, and liquidity strain). Technical indicators are comparatively supportive with the stock trading above major moving averages and a positive MACD, but valuation remains constrained due to ongoing losses and no dividend support.
Positive Factors
Diversified revenue streams
Selling through hospitals, pharmacies and direct OTC channels creates multiple revenue engines and reduces reliance on any single buyer type. This distribution diversity supports steadier demand and resilience to localized disruptions, a durable benefit for cash generation over months.
Negative Factors
Negative shareholders' equity
Negative equity is a structural solvency flag that constrains capital-raising options, creditor confidence and strategic flexibility. Persistent negative equity increases insolvency risk over months and can limit ability to fund R&D, operations, or absorb shocks without dilutive financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified revenue streams
Selling through hospitals, pharmacies and direct OTC channels creates multiple revenue engines and reduces reliance on any single buyer type. This distribution diversity supports steadier demand and resilience to localized disruptions, a durable benefit for cash generation over months.
Read all positive factors
China NT Pharma Group Co., Ltd. (1011) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$683.28M
Dividend YieldN/A
Average Volume (3M)1.68M
Price to Earnings (P/E)―
Beta (1Y)1.17
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees22
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.01
Shares Outstanding948,997,700
10 Day Avg. Volume1,250,790
30 Day Avg. Volume1,683,352
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-0.17
Price to Sales (P/S)1.76
P/FCF Ratio-7.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
China NT Pharma Group Co., Ltd. Business Overview & Revenue Model
Company Description
China NT Pharma Group Company Limited, together with its subsidiaries, engages in the research and development, manufacturing, sales, and distribution of pharmaceutical products in the People's Republic of China and internationally. It manufacture...
How the Company Makes Money
China NT Pharma Group Co., Ltd. generates revenue through multiple streams, primarily by selling its pharmaceutical products to hospitals, pharmacies, and healthcare providers across China and other markets. The company earns income from prescript...
China NT Pharma Group Co., Ltd. Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
15
Very Negative
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 18.66M | 37.96M | 7.37M | 207.09M | 226.70M | 221.73M |
| Gross Profit | 9.57M | 5.26M | 7.37M | 125.29M | 145.46M | 134.90M |
| EBITDA | -7.35M | -8.65M | 1.33M | 10.39M | -17.78M | -52.76M |
| Net Income | -70.92M | -53.36M | -143.59M | -66.41M | -149.54M | -357.60M |
Balance Sheet | ||||||
| Total Assets | 344.41M | 334.07M | 329.12M | 1.01B | 955.36M | 1.30B |
| Cash, Cash Equivalents and Short-Term Investments | 4.63M | 9.62M | 1.52M | 5.93M | 9.44M | 7.69M |
| Total Debt | 316.72M | 375.95M | 344.94M | 826.45M | 832.11M | 851.46M |
| Total Liabilities | 621.29M | 733.18M | 668.69M | 1.25B | 1.17B | 1.27B |
| Stockholders Equity | -276.88M | -399.11M | -339.56M | -241.66M | -211.38M | 16.28M |
Cash Flow | ||||||
| Free Cash Flow | -22.61M | -9.24M | 37.58M | 31.72M | -135.42M | 2.36M |
| Operating Cash Flow | -22.56M | -9.07M | 50.48M | 36.21M | -134.78M | 26.20M |
| Investing Cash Flow | -55.00K | -189.00K | -22.14M | 4.53M | 257.81M | 595.60M |
| Financing Cash Flow | 23.02M | 12.65M | -28.97M | -46.68M | -124.80M | -624.25M |
China NT Pharma Group Co., Ltd. Technical Analysis
Negative
0.84
Price Trends
0.76
Negative
0.79
Negative
0.78
Negative
Market Momentum
-0.01
Negative
44.43
Neutral
52.38
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1011, the sentiment is Negative. The current price of 0.84 is above the 20-day moving average (MA) of 0.73, above the 50-day MA of 0.76, and above the 200-day MA of 0.78, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 44.43 is Neutral, neither overbought nor oversold. The STOCH value of 52.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1011.
China NT Pharma Group Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | HK$206.39M | -6.04 | -6.17% | 3.51% | -5.98% | -81.25% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$926.38M | -2.84 | -48.86% | ― | -43.46% | -96.48% | |
48 Neutral | HK$683.28M | -17.91 | 20.98% | ― | ― | ― | |
48 Neutral | HK$177.84M | -38.07 | -8.95% | ― | 2.54% | 33.33% | |
46 Neutral | HK$416.29M | 43.63 | -1.17% | 7.50% | 59.60% | -351.02% | |
44 Neutral | HK$208.55M | -3.96 | -11.18% | ― | -19.28% | -42.27% |
* Healthcare Sector Average
HK:1011
China NT Pharma Group Co., Ltd.
0.72
0.49
213.04%
HK:0455
Tianda Pharmaceuticals Ltd.
0.10
-0.07
-42.26%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.37
0.02
5.71%
HK:1652
Fusen Pharmaceutical Co., Ltd.
1.26
1.02
425.00%
HK:8329
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H
0.12
-0.02
-15.75%
HK:8622
Huakang Biomedical Holdings Company Limited
0.35
0.05
18.97%
China NT Pharma Group Co., Ltd. Corporate Events
China NT Pharma Advances AI Bone Health Pivot and Secures Liquidity Support After Going-Concern Warning
Jan 28, 2026
China NT Pharma has outlined progress on its transition to an AI-driven, light-asset healthcare model and measures to bolster liquidity, following a previously disclosed going-concern disclaimer in its 2024 annual report. The group is moving to co...
China NT Pharma Shareholders Approve Major Share Issue for Medical Device Acquisition
Jan 15, 2026
China NT Pharma Group has secured shareholder approval at its extraordinary general meeting to issue and allot up to 274,751,679 new shares at HK$0.45 each as consideration for acquiring 100% of the issued shares of Junbinxiongdi Limited, Yuehua L...
China NT Pharma Calls EGM to Approve Major Acquisition and Share Issuance
Dec 24, 2025
China NT Pharma Group has convened an extraordinary general meeting for 15 January 2026 in Hong Kong to seek shareholder approval for the acquisition of 100% of the issued shares in three target companies—Junbinxiongdi Limited, Yuehua Limite...
China NT Pharma Revises Terms of Medical Device Acquisition and Extends Long Stop Date
Dec 18, 2025
China NT Pharma Group has signed a supplemental agreement to revise the payment terms of its previously announced acquisition of 100% of the issued shares in certain target companies, which will be settled through the issuance of consideration sha...
China NT Pharma Group Announces Key Corporate Governance Appointments
Nov 25, 2025
China NT Pharma Group Co., Ltd. has announced significant changes in its corporate governance structure with the appointment of Ms. Li Yifang as the company secretary, authorized representative, and agent for the acceptance of service of process a...
China NT Pharma Group Embraces AI for Orthopedic Market Transformation
Nov 24, 2025
China NT Pharma Group Co., Ltd. is transforming into a high-tech medical enterprise driven by artificial intelligence to adapt to market changes and capitalize on opportunities in China’s growing orthopedic market. The company aims to build ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.